Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is dedicated to the discovery and development of precisely designed cancer therapeutics, transforming science into solutions for patients. The company focuses on next-generation cancer therapeutics, including antibody drug conjugates (ADCs), and employs fit-for-purpose technology such as cell-free XpressCF® to broaden patient benefit and improve patient experience. Sutro is committed to diversity, equity, inclusion, and belonging (DEIB), supporting community and sustainability efforts, and maintaining high standards of integrity and collaboration. The company is also involved in innovative research collaborations, including projects like Project Stella for pediatric AML immunotherapies and partnerships with Fred Hutchinson Cancer Center.
Industries
Nr. of Employees
large (251-1000)
Sutro Biopharma, Inc.
111 Oyster Point Blvd, South San Francisco, CA 94080
Patents
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US-12252552-B2
View DetailsAnti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class
US-12226490-B2
View DetailsAnti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates
US-12144869-B2
View Details
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US-12252552-B2
View DetailsAnti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class
US-12226490-B2
View DetailsAnti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates
US-12144869-B2
View DetailsProducts
Luveltamab Tazevibulin (luvelta)
A folate receptor alpha-targeting ADC in clinical studies for the treatment of platinum-resistant ovarian cancer.
STRO-003
A ROR1-targeting ADC under a global licensing agreement, with potential milestone payments and royalties on sales.
STRO-004
A tissue factor-targeting ADC planned for IND submission in 2025.
XpressCF®
Cell-free protein synthesis technology used for broader patient benefit and improved patient experience.
Environmental Sustainability Initiatives
Includes efforts to minimize environmental footprint through waste reduction, energy-efficient design, and sustainable operations.
Summer Internship Program
Opportunity for students to gain experience and develop skills in the biopharma industry.
Luveltamab Tazevibulin (luvelta)
A folate receptor alpha-targeting ADC in clinical studies for the treatment of platinum-resistant ovarian cancer.
STRO-003
A ROR1-targeting ADC under a global licensing agreement, with potential milestone payments and royalties on sales.
STRO-004
A tissue factor-targeting ADC planned for IND submission in 2025.
XpressCF®
Cell-free protein synthesis technology used for broader patient benefit and improved patient experience.
Environmental Sustainability Initiatives
Includes efforts to minimize environmental footprint through waste reduction, energy-efficient design, and sustainable operations.
Summer Internship Program
Opportunity for students to gain experience and develop skills in the biopharma industry.
Services
Evaluation of individual patient requests for investigational medicines according to eligibility criteria, safety considerations, and regulatory requirements.
Operational management and coordination with clinical sites to monitor enrollment, manage investigational product supply, and mitigate disruptions.
Internal manufacture of clinical materials combined with coordination of third-party manufacturing partners and suppliers to support clinical programs.
Development of analytical methods and quality control testing to support product characterization and release for clinical studies.
Collaborative research with academic centers for early-stage target identification and preclinical development.
Management of regulatory interactions, IRB requirements, and safety reporting processes for investigational product use and clinical programs.
Evaluation of individual patient requests for investigational medicines according to eligibility criteria, safety considerations, and regulatory requirements.
Operational management and coordination with clinical sites to monitor enrollment, manage investigational product supply, and mitigate disruptions.
Internal manufacture of clinical materials combined with coordination of third-party manufacturing partners and suppliers to support clinical programs.
Development of analytical methods and quality control testing to support product characterization and release for clinical studies.
Collaborative research with academic centers for early-stage target identification and preclinical development.
Management of regulatory interactions, IRB requirements, and safety reporting processes for investigational product use and clinical programs.
Expertise Areas
- Cell-free protein expression
- Antibody-drug conjugate development
- Clinical trial management
- Clinical-scale manufacturing and MSAT
Key Technologies
- Cell-free protein synthesis
- Site-specific antibody–drug conjugation
- Clinical-scale biologics manufacturing
- Analytical assay development
News & Updates
Announcement of Greg Chow's appointment as CFO.
Financial results and pipeline updates for Q1 2025.
Details about upcoming investor events.
Announcement of Greg Chow's appointment as CFO.
Financial results and pipeline updates for Q1 2025.
Details about upcoming investor events.
Announcement of Greg Chow's appointment as CFO.
Financial results and pipeline updates for Q1 2025.
Details about upcoming investor events.
Announcement of Greg Chow's appointment as CFO.
Financial results and pipeline updates for Q1 2025.
Details about upcoming investor events.